Ocular TherapeutixOCUL
OCUL
About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees: 267
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
43% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]
23% more capital invested
Capital invested by funds: $990M [Q2] → $1.22B (+$230M) [Q3]
13% more funds holding
Funds holding: 149 [Q2] → 168 (+19) [Q3]
3.63% less ownership
Funds ownership: 93.45% [Q2] → 89.82% (-3.63%) [Q3]
16% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 49
26% less call options, than puts
Call options by funds: $2.34M | Put options by funds: $3.17M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
93%
upside
Avg. target
$15
93%
upside
High target
$15
93%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 41% 1-year accuracy 64 / 158 met price target | 93%upside $15 | Buy Reiterated | 3 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 weeks ago
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024
Positive
Seeking Alpha
1 month ago
Ocular Is Now Thoroughly Derisked
Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), and the trial is expected to close randomization this week.
Neutral
GlobeNewsWire
2 months ago
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.
Neutral
Seeking Alpha
2 months ago
Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV.
Charts implemented using Lightweight Charts™